Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ancrod.

David G Sherman1

  • 1Department of Medicine, University of Texas Health Science Center, San Antonio 78229-3900, USA. sherman@uthscasa.edu

Current Medical Research and Opinion
|October 9, 2002
PubMed
Summary
This summary is machine-generated.

Ancrod, derived from pit viper venom, shows promise in improving neurological outcomes for ischaemic stroke patients. While it reduces blood clot formation, careful monitoring for increased bleeding risk is essential.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enoxaparin versus unfractionated heparin in the prevention of venous thromboembolism after acute ischemic stroke: rationale, design, and methods of an open-label, randomized, parallel-group multicenter trial.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2007
Same author

Prevention of venous thromboembolism, recurrent stroke, and other vascular events after acute ischemic stroke: the role of low-molecular-weight heparin and antiplatelet therapy.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2007
Same author

The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison.

Lancet (London, England)·2007
Same author

Stroke prevention in atrial fibrillation: pharmacological rate versus rhythm control.

Stroke·2007
Same author

Safety and tolerability of arundic acid in acute ischemic stroke.

Journal of the neurological sciences·2006
Same author

Functional status in rate- versus rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy.

Journal of the American College of Cardiology·2005

Area of Science:

  • Neurology
  • Vascular Medicine
  • Pharmacology

Background:

  • Ischaemic stroke affects over 500,000 Americans annually, primarily caused by arterial blockages.
  • Current management focuses on reducing thrombus formation and enhancing blood flow to improve patient outcomes.
  • Ancrod, a biological agent from Malayan pit viper venom, decreases fibrinogen levels, prolonging clot formation time and reducing blood viscosity.

Purpose of the Study:

  • To evaluate the efficacy and safety of Ancrod in treating patients with ischaemic stroke.
  • To assess Ancrod's impact on neurological outcomes and bleeding risk.

Main Methods:

  • Clinical studies involving patients diagnosed with ischaemic stroke.
  • Administration of Ancrod to reduce fibrinogen levels and blood viscosity.

Related Experiment Videos

Main Results:

  • Ancrod treatment demonstrated a beneficial effect on neurological outcomes in stroke patients.
  • A modest increase in bleeding risk was observed as a side effect.

Conclusions:

  • Ancrod presents a potential therapeutic option for ischaemic stroke management.
  • The benefits of improved neurological function must be weighed against the increased risk of bleeding.